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Abstract
Micro RNAs (miRNAs) are a class of small, non-coding RNA species that play critical roles throughout cellular development
and regulation. miRNA expression patterns taken from various tissue types often point to the cellular lineage of an
individual tissue type, thereby being a more invariant hallmark of tissue type. Recent work has shown that these miRNA
expression patterns can be used to classify tumor cells, and that this classification can be more accurate than the
classification achieved by using messenger RNA gene expression patterns. One aspect of miRNA biogenesis that makes
them particularly attractive as a biomarker is the fact that they are maintained in a protected state in serum and plasma,
thus allowing the detection of miRNA expression patterns directly from serum. This study is focused on the evaluation of
miRNA expression patterns in human serum for five types of human cancer, prostate, colon, ovarian, breast and lung, using
a pan-human microRNA, high density microarray. This microarray platform enables the simultaneous analysis of all human
microRNAs by either fluorescent or electrochemical signals, and can be easily redesigned to include newly identified
miRNAs. We show that sufficient miRNAs are present in one milliliter of serum to detect miRNA expression patterns, without
the need for amplification techniques. In addition, we are able to use these expression patterns to correctly discriminate
between normal and cancer patient samples.
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Introduction
MicroRNAs (miRNA) are single-stranded RNA molecules of
about 21–23 nucleotides in length, which function in the
regulation of gene expression. miRNAs are expressed as part of
primary transcripts in the form of hairpins with signals for dsRNA-
specific nuclease cleavage by the ribonuclease Drosha in
combination with an RNA-binding protein. After the precursor
miRNA is released as an approximately 70 nt RNA, it is
transported from the nucleus to the cytoplasm by Exportin-5,
and then is cleaved by Dicer RNase III to form a double-stranded
RNA. Dicer initiates the formation of the RNA-induced silencing
complex (RISC), which is responsible for the gene silencing
observed due to miRNA expression and RNA interference [1,2,3].
MicroRNAs have been found in tissues and also in serum and
plasma, and other body fluids, in a stable form that is protected
from endogenous RNase activity (in association with RISC, either
free in blood or in exosomes (endosome-derived organelles)).
Studies by Lu et al [4] demonstrated the feasibility and utility of
monitoring the expression of miRNAs in human cancer tissue.
They found a high level of diversity in miRNA expression across
cancers, and found that approximately 200 miRNAs could be
sufficient to classify human cancers. Tam [5] adds that because
miRNAs function as managers in gene regulatory networks, they
are distinct from other biomarkers because they have a pathogenic
role in the disease process and are not by-products of the disease
state. Because miRNAs function by specific binding to their
targets, polymorphisms (SNP) within the sequence of miRNAs or
their target mRNAs can lead to disease, including cancer. These
miRNA-specific SNPs can influence the risk of disease and can
also be used in the diagnosis of these diseases [6]. Deregulated
miRNAs have been described from numerous human cancers
including breast, lung, colon, ovarian, and prostate cancer.
Mitchell et al [7] found that miRNAs originating from prostate
cancer tissue enter circulation and can be used to distinguish
patients with prostate cancer from healthy controls and established
a blood-based PCR approach for the detection of human prostate
cancer. A similar approach was used to detect serum miRNA from
ovarian cancer patients [8]. Taylor and Gercel-Taylor [9]
investigated the use of circulating exosomes in the diagnosis of
cancer. They found that the miRNA content of ovarian tumor
cells and circulating exosome was similar and could be used to
distinguish cancer patients from patients with benign ovarian
disease and from normal controls.
miRNA signatures from normal and cancerous tissues have
been used to classify several types of cancer and may also allow
clinicians to determine a treatment course based on the original
tissue type. It may also be possible to use miRNA expression
patterns as a biomarker to monitor the effect of therapy on cancer
progression [2]. Because miRNA expression profiles parallel the
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miRNAs can be used to effectively type tissues, they are potentially
superior markers than messenger RNAs for cancer diagnosis [4].
The potential for the use of serum miRNAs as biomarkers of
disease and as targets of therapeutics is promising [10], since it
would mean a non-invasive, accurate test for cancer. In this study,
we demonstrate that serum miRNAs can be used to discriminate
between cancer patient sera and normal donor sera, using a simple
microarray assay that requires no amplification step.
Results
Serum microRNA extraction
We have determined that a sufficient quantity of miRNAs is
present in less than 1 ml of human serum to produce a detectable
signal on a microarray using fluorescence or electrochemical
detection (ECD). Using a simple phenol/chloroform extraction
protocol, we recovered approximately 1.3 mg of serum RNA from
each 800 ml of serum (average of 18 samples; standard deviation
0.3). The resulting pattern of miRNA expression could be used to
distinguish between cancer patients and normal donors.
The approximate size of the small RNAs recovered from plasma
was determined by isolating large RNA fragments (low ethanol
concentration) and small RNA fragments (high ethanol concen-
tration) using the Invitrogen PureLink miRNA isolation kit, after
acid phenol/chloroform extraction and precipitation. The two
RNA size fractionations were labeled with biotin (Mirus) and
hybridized to a microarray. Results (not shown) indicated that the
vast majority of signal was from the small RNA fraction, which
was similar to the signal from the un-fractionated sample.
DNA contamination of extracted serum nucleic acid was
examined by comparison of an extracted sample that was split,
and half treated with DNase I. After labeling both treated and
untreated samples with biotin and hybridizing to different sectors
of the same 462K array, very little difference could be seen
between treated and untreated samples (r
2=0.9 and 0.96
respectively for two replicates) indicating that little DNA
contaminates samples (data not shown).
Assay sensitivity and stability
The sensitivity of our miRNA assay was determined by adding
dilutions of a synthetic RNA oligonucleotide to our assay during
serum extraction. We were able to detect approximately 4,000
copies of serum microRNAs per microliter of serum (Figure 1).
This detection level is similar to that reported in Mitchell et al [7]
for the prostate cancer specific microRNA miR-141 using
TaqMan assays. miRNA microarrays are relatively more sensitive
than standard expression microarrays because small oligonucleo-
tides tend to have better hybridization kinetics than larger RNA or
DNA molecules. For miRNAs, both their protection from
digestion by various cellular factors, and their small size contribute
to their detection in serum by microarrays at levels that are as low
as those seen with methods that would otherwise be considered
more sensitive.
We have also determined that data collected from the same
serum samples after being frozen at 280uC for 1 week after the
Figure 1. Assay sensitivity. RNA miRNA analog oligonucleotides, at concentrations ranging from 0 to 40 million copies per microliter, were spiked
into 400 ul of serum after the addition of RLT buffer. RNA was then extracted from the serum using phenol/chloroform extractions and an ethanol
precipitation. Samples were then labeled and hybridized on a microarray. Vertical bars indicate array signal intensities for specific miRNA probes
representing the wild type sequence (Wild) and probes with two internal mutations (mut) for (A) oar|miR-431 and (B) oar|miR-127. Scales for the 4,000
and 0 copies data points (boxed in left panels) are expanded in the right panels: (C) oar|miR-431, and (D) oar|miR-127.
doi:10.1371/journal.pone.0006229.g001
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MicroRNAs from aliquots of 2 serum samples from cancer
patients (1 prostate and 1 colon) were extracted, labeled and
hybridized to arrays, and after one freeze/thaw event, new
aliquots were again extracted, labeled and hybridized to a second
array. Data sets, from re-assayed prostate cancer sample 811 and
colon sample 792, showed strong correlations when raw array data
were compared (r
2=0.94 and 0.96 respectively). This result
indicates that the assay is reproducible and stable over time.
Serum microRNA data analysis
Several prostate, ovarian, colon, breast and lung cancer serum
samples as well as normal male and female donor sera have been
analyzed on the pan-miRNA microarray to ascertain serum
miRNA profiles and to confirm the specificity of the profiles for
different cancers and normal donors. Several data analysis
methods have been tested to determine the most relevant method
for the discrimination of cancer versus normal. For preliminary
analysis, we log2-transformed serum miRNA probe signals from a
normal donor and compared this data to log2-transformed probe
data from a prostate cancer patient and from a prostate cancer cell
line. Although both the prostate cancer serum sample and the
prostate cancer cell line (22Rv1) sample showed up-regulation
compared to a normal serum sample, they did not show much
similarity to each other. At this point, we simply note a relative up-
regulation of serum miRNAs in cancer as compared to serum from
normal donors (Figure 2).
We first set out to define a minimal set of probes that would
allow us to discriminate between prostate and normal serum
samples. Signal from each miRNA probe was first background
corrected using negative control probes. Subsequently, each
miRNA probe was expressed as the natural log of the ratio
between itself and the same probe in a normal human male serum
sample. This gives a value of 0 for all the base serum sample
probes and an up or down regulation with respect to that sample
(normal) for all the other samples (normal and cancer). Figure 3
shows the ratios of a subset of probes that passed multiple criteria.
All prostate cancer probe data sets were filtered to remove all
probes whose perfect match signal was not greater than its mutant
signal. Fifteen miRNAs were found to be over-expressed in serum
from all stage 3 and 4 prostate cancer patients (miR-16, -92a, -103,
-107, -197, -34b, -328, -485-3p, -486-5p, -92b, -574-3p, -636, -
640, -766, -885-5p) with respect to 8 normal controls (Figure 3).
This analysis also showed a slightly elevated signal for miR-141 in
stage 3 and 4 prostate cancer patient sera (mean=829,
STD=201) over normal donor sera (mean=555, STD=64);
which is in agreement with data reported by Mitchell et al [7]
using RT-PCR.
In Figure 4, we have plotted z-score-corrected signal intensities
for three hybridizations. Z-score normalization was computed by
subtracting the signal at each probe by the mean of the test probes
from the entire hybridization, and then, by dividing that value by
the standard deviation of the signal across test probes, across each
hybridization. This normalization yields probe signals that are
centered and normalized to a mean of 0 and a standard deviation
of 1.0. For each plot, signal was sorted from highest to lowest
intensity, and plotted as a solid line. Perfect match/mismatch
(pm/mm) ratios were plotted as open triangles over the signal
intensity line. Clearly, probes with higher intensities have
significantly higher pm/mm ratios. For signal from a miRNA to
be considered significant, its perfect match (wild-type anti-sense)
probe signal must be greater than that of its double mutant
negative control (mm) probe. Specifically, the pm/mm ratio must
be greater than 1.5 (plotted on the right-hand side y-axis). By this
metric, at least 34 probes were considered significant for the
normal serum sample (Figure 4A). For the prostate cancer cell line
22Rv1 sample and prostate cancer serum sample (Figure 4 B and
C), there were 57 and 62 significant probes respectively. At the
simplest level, the fact that most of the probes that have high signal
also have high pm/mm ratios, indicates that the signals we are
reading are real. We also performed several non-miRNA negative
control hybridizations. For these hybridizations, although some
Figure 2. Up-regulation of cancer sera miRNAs over normal donor sera miRNAs. Log transformed normal donor serum miRNA signals (blue
line) were compared to miRNA array signals from a prostate cancer cell line 22Rv (open squares) and from a prostate cancer patient (closed
diamonds). In general, cancer and cell line miRNAs seem to be up-regulated when compared to normal donor serum miRNAs.
doi:10.1371/journal.pone.0006229.g002
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a corresponding increase in the pm/mm ratios (not shown).
Hierarchical clustering. Hierarchical clustering was used to
group samples from different disease and normal states (Figure 5).
The dataset used for clustering contained 35 serum samples that
were a mixture of normal serum and cancer serum samples of
diverse types and severity (stages) (see Tables 1 and 2). Since most
of the miRNAs used on the microarray are not present at
detectable levels in most serum samples, clustering was only
performed on a subset of the miRNAs. This subset was drawn
from the group of miRNAs that were judged to be significant.
Only signal from miRNA probe sets that were found to have been
significant in at least 5 hybridizations across the entire data set
were taken and used for further analysis. Signal from test probes
(wild-type anti-sense) was log2-transformed. These probes were
then normalized by conversion to Z-score. Only test probes, not
any of the negative controls or spike-ins, were used for this
calculation. Signal was then thresholded based on significance.
Hierarchical clustering was performed using a program written in-
house that uses the spearman rank correlation as the distance
function. The output for this program is a dendrogram that was
displayed using the program Treeview [11]. Clustering indicates a
clear demarcation between normal and most cancer samples
(Figure 5).
Heat Map Analysis. To further explore the miRNAs
responsible for the clustering, Heat maps were used to look for
similarities between miRNA expression patterns within each
sample. This method is most effective when rows and columns
are ordered to allow these patterns to be easily identified.
Clustering was thus used to give this ordering (by identifying
miRNAs that have similar expression patterns, and arranging
them in close proximity). This data was ported to the open source
program, Cluster [12]. The raw data for both sample and miRNA
signal were median centered and then clustered using average
linkage, spearman rank coefficient as a distance function.
Heatmaps were displayed using Treeview [11]. This method
resulted in a clear ordering of the samples taken from our test-set
(Figure 6). Samples were labeled with a unique identifier. Serum
samples from patients with colon, prostate, ovarian, breast and
lung cancer in various stages of disease and treatment were used in
this dataset. This analysis resulted in two main branches: one
major cluster of sequences containing most of the cancer samples,
and a second branch containing the normal group along with a
second cancer group (Figure 6).
Decision Tree Analysis. For each miRNA mature region,
two controls were written on the chip: a sense wild-type probe (s),
an anti-sense wild-type (PM) form and a double mutant control
(MM). This probe set was used to evaluate significance as well as
intensity of each miRNA mature form. For each hybridization, the
raw signal was extracted and probes were grouped by the miRNA
that they were designed for. PM signal was log2 transformed, and
Z-normalized. For the classifier and for the focused cancer versus
normal hierarchical clustering, we used a simple heuristic to
determine if a probe was indeed present. For each miRNA that
was evaluated, we counted a signal significant if the signal for PM/
MM .1.0. If so, then the Z-normalized log2 (signal) was used for
that miRNA, otherwise the probe data for that particular probe
was not used. Normalization was thus performed over anti-sense
wild-type probes across the chip; however, only data from
significant probes were used for clustering and classification.
Data Mining was performed using the WEKA package [13].
Normalized probe intensity data was converted into ARFF format
and input into the WEKA program. Hybridizations were grouped
into two classes, ‘cancer’ and ‘normal’. We used the CfsSubsetEval
routine to choose miRNA’s (attributes). This method gave the best
classification of the data into the two classes. This routine assesses
the predictive ability of each attribute as well as the degree of
redundancy among each miRNA. It prefers attributes that are
highly correlated within each class, but that have low inter-
correlation. The choice of attributes was performed using 10-fold
cross-validation, and selection of the 28 best attributes was based
upon their being selected at least 30% of the time.
We next extracted signal from each hybridization for just this
selected set of miRNA’s. In Figure 7A, two different classifiers
Figure 3. Analysis of microRNA data for normal and prostate cancer sera. After data set normalization, the natural log of the ratio of the
signal for a specific probe over the same probe from the normal serum sample was taken. 15 miRNAs showed up-regulation in all stage 3 and 4
prostate cancer samples when compared to sera from normal male donors. These miRNAs are listed below each data set. Five stage 3 and 4 prostate
cancer sera (Yellow), and 8 normal male donor sera (red) were analyzed. Vertical lines indicate plus or minus one standard deviation of the mean.
doi:10.1371/journal.pone.0006229.g003
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network and an instance-based method called K* [14] were able to
clearly differentiate the two classes within 36 samples. Clustering
was next performed using the Cluster program from Eisen et al.
[12]. Average linkage was used as the tree-building criteria and
Spearman rank correlation was used as the distance function.
Figure 7 B shows a much-improved separation of normal vs.
cancer patient samples.
Analysis of coded samples. miRNA microarray data from
cancer patients and normal donor sera were coded to remove any
indication of disease status and submitted for analysis. Using the
subset of attributes described above and in Figure 7, 16 single-
blinded samples were added to the dataset and analyzed with the
classifier. The k-star classifier was able to call 16/16 samples
correctly as either from cancer patients or normal donors, while
the Bayes Network classifier produced 3 misclassifications out of
16 (data not shown).
Discussion
miRNA expression signatures have a potential role in the
diagnosis, prognosis and therapy of human diseases, including
cancer, heart disease, viral infections and inflammatory diseases
[1–4,10,15–25]. Deregulation of miRNAs in cancer can be caused
by chromosomal deletions, amplifications and translocations; by
hypermethylation of CpG islands; and by regulation of transcrip-
tion and post-transcriptional processing [1,2,23]. Aberrant expres-
sion of miRNAs can influence cancer progression by affecting the
expression of oncogenes or tumor suppressors, and miRNAs, such
as the miR-17-92 cluster, can function directly as oncogenes
[1,2,23]. miRNAs are also involved in cancer through their effect
on the cell cycle, apoptosis, metastasis, and angiogenesis [1,2,23].
Several studies have detailed the miRNAs that are associated
with cancers [15,23,26–32]. Most of these studies have used biopsy
samples, archival tissues or cancer cells [5,33–37]; or have used
miRNAs extracted from paraffin embedded or formalin fixed
tissues [38]. By comparing non-cancerous tissues surrounding
cancerous tissues, or normal donors versus cancer patients, those
miRNAs that are up or down regulated can be identified, often
after PCR amplification. Many studies have been published
describing the specificity of miRNAs for different types of cancers,
cancer stages and cancer treatments and several reviews have been
published that summarize the most recent information on the roles
of miRNAs in cancer [1,2,5,6,15,23,25,32]. These studies
demonstrate the utility of miRNAs in both diagnosis and prognosis
of several cancers and also differentiate between cancer and
benign disorders [34]. While numerous studies have led to an
understanding of miRNAs at a tissue or cell level, there is a paucity
of data in serum studies hampering their use in routine diagnosis.
Recently a series of studies has been performed on miRNAs
present in serum [7–9,39–41]. In a recent report, miRNAs were
shown to be significantly elevated in pregnant versus non-
pregnant women [40]; and in another study, placental miRNAs
were shown to be present in maternal plasma [42]. In these
studies, the miRNAs were found to be very stable to storage, and
also to any RNAse degradation. miRNAs have recently been
shown by Mitchell et al [7] to circulate in serum of prostate cancer
patients [7]. In particular, miR-141 could differentiate prostate
cancer patients from normal individuals [7]. In a work by Taylor
and Gercel-Taylor [9], circulating tumor exosomes were isolated
from serum of ovarian cancer patients using magnetic beads and
an antiEpCAM antibody. miRNAs were then extracted, labeled
and detected by microarray. This approach, using larger volumes
of serum, indicated that eight diagnostic miRNAs were up-
regulated in cancer exosomes: miR-21, miR-141, miR-200a, miR-
200c, miR-200b, miR-203, miR-205, and miR-214. To date
however, no routine assay is available for examining miRNA
signatures in serum or in the plasma of cancer patients.
One issue that appears in these studies is the fact that the
miRNA expression patterns seen in serum are not identical to
those seen from miRNAs taken directly from cancer cell lines. In
our study, we found that although both the prostate cancer serum
sample and the prostate cancer cell line (22Rv1) sample showed
up-regulation compared to normal serum sample, they did not
show much similarity to each other. This seeming discrepancy
could be taking place for a number of reasons. The most obvious
of which is the possibility that samples taken from the cell lines
themselves are not representative of what appears in the serum.
We can speculate that the most obvious source of miRNAs that
appear in the serum is a product of tumor cell lysis; however, it
may also be possible that their appearance in the serum is the
product of a form of active transport involving the formation of
Figure 4. Analysis of signal from perfect match (wild type) and
miss-match (double mutant) miRNA probes (pm/mm ratio). (A)
Analysis of signal from normal serum; (B) Analysis of signal from 22Rv1
cell culture; and (C) signal from prostate cancer patient serum. Z-scores
(blue lines) were determined by subtracting the signal at each probe by
the mean of the test probes from the entire hybridization, and then, by
dividing the resulting value by the standard deviation of the signal
across test probes, across the entire hybridization.
doi:10.1371/journal.pone.0006229.g004
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PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6229Figure 5. Hierarchical clustering of microarray data (Spearman). Cancer samples and normal donor samples (brackets) were clustered using a
hierarchical clustering program to show sample-to-sample relationships. Sample labels include donor condition (cancer type or normal), sample lot
number (last three digits), gender, and cancer stage (2 – 4, or 0 for normal). Labels marked with a or b indicate repeat testing of the same sample.
doi:10.1371/journal.pone.0006229.g005
Table 1. Summary of human cancer serum samples tested in this study.
CANCER PATIENT SERUM SAMPLES
LOT NUMBER GENDER AGE STAGE CANCER TYPE TREATMENT
BRH233781 Female 63 4 OVARIAN CANCER Carboplatin, Taxotere
BRH233782 Female 66 4 OVARIAN CANCER Carboplatin, Gemzar
BRH233787 Female 69 4 NON-SMALL CELL LUNG Zofr, Deca, Carb, Neul, Veps
BRH234151 Female 68 4 SMALL CELL LUNG Topotecan
BRH234153 Male 62 3 SMALL CELL LUNG Zometa
BRH237121 Female 69 1 COLON CANCER None
BRH237122 Female 67 2 COLON CANCER Ferrlecit
BRH237123 Female 85 2 COLON CANCER None
BRH233792 Female 63 2 COLON CANCER None
BRH237120 Female 87 3 COLON CANCER Zometa
BRH233796 Male 69 3 COLON CANCER 5FU
BRH233798 Female 76 3 COLON CANCER None, Pretreatment
BRH249639 Male 47 4 COLON CANCER 5FU
BRH234157 Female 80 4 BREAST CANCER Femara, Zometa
BRH234158 Female 44 4 BREAST CANCER Xeloda, Zometa
BRH233808 Male 65 4 PROSTATE Taxotere, Zometa
BRH233809 Male 62 4 PROSTATE Taxotere, Zometa
BRH233811 Male 72 3 PROSTATE Lupron, Zometa
BRH233812 Male 61 3 PROSTATE None
BRH233814 Male 59 3 PROSTATE Taxotere
BRH249616 Male 64 2 PROSTATE None
doi:10.1371/journal.pone.0006229.t001
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miRNA expression patters derived from cell-line and tumor with
those that are serum-derived.
Information on the use of miRNAs as biomarkers is predom-
inantly associated with studies on tissue samples or cancer cell
lines. Distinct patterns of miRNA expression are able to
distinguish between cell type and stage in various cancers. This
bodes well for diagnostic and prognostic applications of miRNA
profiles. It also indicates there is clearly a need to define the
expression profiles of miRNAs in serum of cancer patients and
compare these to profiles observed in the serum of individuals
representing a range of diseased and healthy states. It is
anticipated that miRNA profiles in serum have the potential to
be early markers for cancer detection and will also play a role in
the monitoring of disease status during chemotherapy.
In this study, we have determined that a sufficient quantity of
miRNAs is present in one ml of human serum to produce a
detectable signal on a microarray using fluorescence or electro-
chemical detection. At the simplest level, this study has shown that
serum miRNAs are up-regulated in cancer patients as compared
to normal donors. In a comparison of stages 3 and 4 prostate
cancer sera and normal donor serum miRNA levels, we found that
15 miRNAs (miR-16, -92a, -103, -107, -197, -34b, -328, -485-3p, -
486-5p, -92b, -574-3p, -636, -640, -766, -885-5p) were up-
regulated in serum from prostate cancer patients compared to
normal donor sera.
Heat Map and cluster analyses show that serum miRNA
signatures can also be used to separate cancer patients and normal
donors in most cases. Sixty-five miRNAs (see Figure 6) were used
in a Heat Map analysis that isolated 21 cancer samples, plus 3 re-
assayed samples, from normal samples. Sixteen cancer samples
clustered together, while five cancer samples formed a separate
cluster within the normal sample cluster. Cluster analysis (see
Figure 5) was also used to distinguish 21 cancer samples from 12
normal samples. Three cancer samples that were re-analyzed after
freeze-thawing and storage, also clustered with the cancer samples
We have also shown that serum miRNAs can be detected at a
level similar to that reported for TaqMan PCR from serum,
approximately 4,000 copies per ul [7], and that the assay is stable
for repeated sample testing after storage. The relative sensitivity of
miRNA microarrays over standard expression arrays could be due
to the hybridization kinetics of small oligonucleotides. Small
molecules tend to have better hybridization kinetics than larger
RNA or DNA molecules. Indeed, most of the thermodynamic
models for predicting DNA hybridization behavior were devel-
oped using short oligonucleotides [43]. Many of the conclusions
drawn from such studies do not apply when larger molecules are
used as secondary structure, non-specific binding, and various
other unforeseeable effects interfere with predicted hybridization
behavior. For miRNAs, both their protection from digestion by
various cellular factors, and their small size contribute to their
detection in serum by microarrays at levels that are as low as those
seen with methods that would otherwise be considered more
sensitive, such as RT-PCR. The sensitivity of the microarray
platform used here has allowed us to monitor miRNA from a small
volume of serum and to classify sera as either from normal donors
or from cancer patients.
Our results, in general, agree in many cases with previously
published studies. However, differences in our results from other
studies could result from several factors: 1) Serum miRNA expression
profiles do not directly correspond to tissue profiles. The low levels of
miRNAsinserum are better suited to studies of up-regulation and not
down-regulation. In addition, it is unlikely that there is a direct
correspondence between tissue miRNA levels and serum miRNA
levels due to the possible mechanisms of miRNA release into
circulation (cell lysis or exosome release [9]) [8], and to the release of
miRNAsintocirculation fromother tissuesas aresult ofthe canceror
other related or non-cancer related conditions; 2) Different miRNA
labeling techniques can produce different expression profiles. For
example, ULS chemical labeling (Mirus and Kreatech kits), which
only targets G residues, produces signal intensities that are directly
proportional to the number of G residues in the miRNA. In contrast,
labeling by incorporating modified nucleotides or label into an
extended poly A tail, or by labeling with a modified primer by first
strand cDNA synthesis, should produce a more even label; 3) We
foundthatamplificationtechniquessuchasRT-PCRorT7promoter
expression, produce different expression patterns on arrays when
compared to un-amplified samples. This could be due to differential
efficiency in the amplification process. In addition, the limited
quantity of miRNAs in human serum is not sufficient for column
purification, which is commonly used for tissue miRNA purification.
An example of published data from two different miRNA
expression profiling techniques that do not show strong agreement
is illustrated in the following comparison. Schetter et al [44]
labeled colon cancer tissue miRNAs by reverse transcriptase
extension with a labeled primer and hybridized the target to a
microarray, while Monzo et al [45] determined colon cancer tissue
miRNA expression levels by TaqMan RT-PCR. When the 26 up-
regulated miRNAs from the Schetter study are compared to those
from the Monzo study, only 14 miRNAs are in agreement (54%).
In a similar comparison of up-regulated prostate cancer tissue
miRNAs from studies by Tong et al (TaqMan data [46]), Porkka et
al (array data [47]), and Ambs et al (array and TaqMan data [33]),
very little overlap of miRNA expression data can be seen: little or
no overlap in data between Tong et al and Porkka et al, and only 1
of 33 and 1 of 34 miRNAs were in agreement for Tong et al
compared to Ambs et al, and for Porkka et al compared to Ambs
et al, respectively. Of the 15 upregulated serum miRNAs we report
for prostate cancer, 4 are in agreement with data from Ambs et al,
and 2 are in agreement with data from Porkka et al.
Table 2. Summary of normal donor serum samples tested in
this study.
NORMAL DONORS
LOT NUMBER GENDER AGE
BRH233823 Male 40
BRH233824 Male 61
BRH233825 Male 44
BRH233826 Male 42
BRH233827 Male 49
BRH233828 Male 50
BRH233829 Male 41
BRH237135 Male 31
BRH237124 Female 56
BRH237125 Female 22
BRH237126 Female 22
BRH237127 Female 69
BRH237131 Female 48
BRH237132 Female 47
BRH237133 Female 32
doi:10.1371/journal.pone.0006229.t002
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PLoS ONE | www.plosone.org 7 July 2009 | Volume 4 | Issue 7 | e6229Figure 6. Heat maps of microRNA array data. The set of miRNAs used for analysis was chosen based on significance in at least 5 hybridizations.
A probe-set was judged significant if the ratio of perfect-match (PM)/mismatch (MM) probes was greater than 1.5.For each hybridization in the
analysis, only significant signal was used for the clustering. Signal for those miRNAs whose signal was judged significant by PM/MM ratios was Log 2
converted. Then the signal was median normalized over that hybridization and Average Linkage Clustering was performed using a Spearman Rank
Correlation. Clustering was visualized using the program TreeView [12]. Green indicates negative values and Red indicates positive values. Samples
are identified as either normal (blue bar) or cancer (yellow bar) at the top of the figure. miRNA names are listed to the right and sample identifications
are listed above.
doi:10.1371/journal.pone.0006229.g006
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PLoS ONE | www.plosone.org 8 July 2009 | Volume 4 | Issue 7 | e6229Figure 7. Cancer vs. Normal Classifier. Data Mining was performed using the WEKA package [13]. miRNA probes (attributes) were chosen using
an attribute selection routine called CfsSubsteEval. (A) 28 miRNAs were found using this method. Two distinct classifier methods, both the Bayes
network implementation and K* methods [14] were able to correctly classify these samples (using 10-fold cross-validation). The results for both
classifier runs are displayed as a confusion matrix on the right. (B) Hierarchical clustering of normal and cancer samples was performed using signal
from these 28 miRNAs. Red blocks are highly expressed, green are considered down-regulated and black blocks are non-significant as judged by PM/
MM criteria described in the text. Samples are identified as either normal (blue bar) or cancer (yellow bar) at the top of the figure. miRNA names are
listed to the right and sample identifications are listed above.
doi:10.1371/journal.pone.0006229.g007
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documented data set. We do not yet know the affects of gender,
age and cancer treatment on miRNA levels in serum. Radiation
and chemotherapies that result in remission of cancer should also
result in a change in the serum miRNA profiles. Wong, et al. [48]
have shown that plasma levels of miR-184 were elevated in
patients with squamous cell carcinoma of the tongue, and that
plasma miRNA levels were reduced after surgical removal of the
tumor. This would indicate that cancer treatment does have an
affect on the levels of cancer-specific miRNAs in circulation. The
samples used in this study were from cancer patients that were
treated by chemotherapy in most cases. Because we do not have
detailed information on the results of treatment on cancer
progression or remission we cannot include this variable in our
analysis. Additional studies with well-documented patient samples
will be needed to address this question.
Materials and Methods
DNA array synthesis and microarray configuration
Arrays for serum miRNA analysis were constructed with 547
human miRNA sequences obtained from the Sanger Database
version 10.0 which appeared on 8/2/07. Because of limited space
on the array, the probe list was modified to exclude a few newer
miRNAs that had recently been added. The array includes
miRNA probes for all studies referenced by this paper. Three
probes were written for each miRNA: an anti-sensed wild-type
version, a double-mutant control probe, and a sense control
version (Figure 8). Antisense controls were not included if the
corresponding antisense miRNA existed in the databases. The
double mutant control mutations were screened in order to
maintain the same notional melting temperature (Tm) as the wild-
type Tm. They were also designed to avoid perturbing or creating
any secondary structure that might appear in the wild-type probe.
In addition to the 547 human miRNAs, we also included as
controls, four sheep, three C. elegans, and two human sequences.
These arrays have been initially evaluated using a Cy5
fluorescence detection system, but can be converted to a more
sensitive electrochemical system (ECD: ElectraSense
H) [49].
Additional microRNAs can be easily added to the array as they
are identified in the Sanger database.
22Rv1 cell culture
22Rv1 human prostate cancer-derived cells were cultured in
standard plastic tissue culture plates in RPMI medium 1640
(GIBCO) supplemented with 10% FBS and 1% penicillin-
streptomycin at 37uC in a 5% CO2 incubator. Cells were
harvested in Qiagen RLT buffer and extracted with phenol/
chloroform as described below.
Human serum samples
Human serum samples were purchased from Bioreclamation,
Inc, Hicksville, NY and include: stages 2 to 4 prostate, stages 1 to 4
colon,stage 4 ovarian,stage 4 breast,and stages 3 and 4 lung cancer
sera (Table 1); and sera from normal male and female donors
(Table 2). All cancer samples have associated patient data including
age, race, gender, chemotherapy, and stage of disease. No
information on treatment outcome or on radiation therapy was
supplied with samples. Samples werestored atminus 80uC until use.
MicroRNA extraction, labeling and hybridization
Extraction. An aliquot of 400 ml of each serum sample was
mixed with 500 ml lysis buffer (RLT, Qiagen, Valencia, CA) and
800 ml acid phenol: Chloroform (Ambion, Foster City, CA),
vortexed for 30 seconds and centrifuged at 16000 rcf for 10 min at
25uC. The aqueous phase was extracted 26with an equal volume
of acid phenol:chloroform and centrifuged at 16000 rcf for 10 min
at 25uC. The resulting aqueous phase was then precipitated with
0.1 vol 5 M NaCl, 2 ml precipitation enhancer (Mirus, Madison,
WI), 2 ml GlycoBlue (Ambion) and 2.5 vol 100% ethanol at
220uC for at least 1 hr. After centrifugation at 4uC for 30 min,
the pellets were washed 26with 75% ethanol and then air-dried.
Precipitated RNA was resuspended in 50 ml molecular grade water
(Ambion) and quantified with a NanoDrop ND-1000
spectrophotometer (Thermo Scientific, Wilmington, DE).
Labeling. Approximately one mg of isolated RNA was labeled
with a Mirus miRNA Biotin labeling kit (MIR8450) following
manufacturers directions. Briefly, 1 mgR N Aw a sd i l u t e dt o8 6ml
with water and 10 mlo f1 0 6 buffer was added followed by 4 ml
LabelIT biotin labeling reagent and incubation at 37uCf o r1h r .T h e
reaction was stopped with 10 mls t o pr e a g e n ta n dt h es a m p l e
precipitated as described above. The dried pellet was resuspended in
5.1 ml water.
Hybridization. Sectored array chambers (4 chambers per
array) (CombiMatrix 462K arrays
TM) were each filled with 30 ml
of Pre-Hybridization Solution (CombiMatrix Corp) and incubated
for 10 min at 45uC. MicroRNA was mixed with 9 ml2 0 6SSPE
(Ambion), 4.8 ml BSA at 50 mg/ml (Ambion), 3.6 ml deionized
formamide (Sigma) and 7.5 ml of 10% SDS (Ambion) and heated
to 95uC for 3 min. 30 ml of each sample were added to sectored
hybridization chambers, sealed with aluminum tape, and
incubated at 45uC for 16 hr with rotation. After hybridization,
arrays were washed 26 with 26 SSC with 0.1% SDS at room
temperature (RT) for 10 sec (CombiMatrix Corp), 26 with 26
SSC at RT for 10 sec and then washed 16with 0.26SSC at RT
for 10 sec each.
Arrays were blocked with 56 PBS/Casein Blocking Buffer at
RT for 10 min and then labeled with either Cy5 labeling solution
for fluorescence scanning or HRP Biotin Labeling Solution
Figure 8. Probe design scheme for miRNA array. Sequences for miRNA probes were taken from the Sanger database version 10.0 (released, 8/
2/2007). We generally used only the predominantly expressed form for each miRNA precursor. This was done to save space on the array. The final list
included all of the dominant miRNA forms from the studies referenced in this paper [4,8,18]. Three probes were designed for each mature miRNA
sequence: 1) antisense to wild type; 2) double mutated antisense (boxes); and 3) sense negative control probes (included if the corresponding
sequence was not found in miRNA databases). Hsa-let-7a is used here as an example of our approach to probe design.
doi:10.1371/journal.pone.0006229.g008
Cancer Detection with miRNAs
PLoS ONE | www.plosone.org 10 July 2009 | Volume 4 | Issue 7 | e6229(CombiMatrix) for ElectraSense reading (CombiMatrix) and
incubated for 30 min at RT. Arrays were then washed 26 with
Biotin Wash Solution (26 PBST) for 30 sec each at room temp
and again washed 26 with 26 PBS followed by scanning for
fluorescence, or washed 26 with TMB Rinse Solution (Combi-
Matrix), followed by one wash with TMB substrate (CombiMatrix)
and scanning with an ElectraSense reader (CombiMatrix) after
fresh TMB was added.
Determination of assay sensitivity
To determine the sensitivity of our assay, commercially
purchased RNA miRNA analog oligonucleotides (IDT), at
concentrations ranging from 0 to 40,000,000 copies per microliter,
were spiked into 400 ml of normal human serum after the addition
of RLT buffer. RNA was then extracted from the serum using acid
phenol/chloroform extractions and an ethanol precipitation.
Samples were then labeled with biotin and hybridized on a
microarray as previously described.
The approximate size of the small RNAs recovered from serum
was determined by isolating large RNA fragments (low ethanol
concentration) and small RNA fragments (high ethanol concen-
tration) using the Invitrogen PureLink miRNA isolation kit, after
phenol/chloroform extraction and precipitation. The two RNA
size fractionations were labeled with biotin (Mirus) and hybridized
to a microarray as described above.
DNA contamination of extracted serum nucleic acids
Purified nucleic acid from a serum sample was split into two
aliquots (DNase I-treated and untreated). One aliquot was digested
with DNase I (New England Biolabs, Ipswich, MA) for 30 min at
37uC, following manufacturer’s protocol, and then heated to 85uC
for 15 min. This sample was then precipitated with NaCl and
ethanol and both DNase I-treated and untreated samples were
labeled with a Mirus biotin-labeling kit as described above.
GEO Database
Array data accession numbers: GPL8686; GSE16512;
GSM414832 - GSM414867.
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